These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20610708)

  • 1. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.
    Sato K; Izumi T; Misawa N; Kobayashi T; Yamashita Y; Ohmichi M; Ito M; Takaori-Kondo A; Koyanagi Y
    J Virol; 2010 Sep; 84(18):9546-56. PubMed ID: 20610708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
    Sadler HA; Stenglein MD; Harris RS; Mansky LM
    J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
    Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
    J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
    De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
    Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
    J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
    Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
    J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.
    Kourteva Y; De Pasquale M; Allos T; McMunn C; D'Aquila RT
    Virology; 2012 Aug; 430(1):1-9. PubMed ID: 22579353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
    Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
    J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
    Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
    Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
    Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
    J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
    Pillai SK; Wong JK; Barbour JD
    Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
    Haché G; Shindo K; Albin JS; Harris RS
    Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
    Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
    J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo.
    De Pasquale M; Kourteva Y; Allos T; D'Aquila RT
    PLoS One; 2013; 8(10):e76002. PubMed ID: 24146808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.